{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T07:42:08Z","timestamp":1792395728876,"version":"4.4.0"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PI 21\/01310"],"award-info":[{"award-number":["PI 21\/01310"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PI 24\/01769"],"award-info":[{"award-number":["PI 24\/01769"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PI25\/01197"],"award-info":[{"award-number":["PI25\/01197"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.aohep.2026.102468","type":"journal-article","created":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:39:58Z","timestamp":1791729598000},"page":"102468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anticoagulation in cirrhosis: Indications, drug selection, and disease-modifying potential"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9254-3891","authenticated-orcid":false,"given":"Luis","family":"T\u00e9llez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7989-7808","authenticated-orcid":false,"given":"Antonio","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6039-0272","authenticated-orcid":false,"given":"Jes\u00fas","family":"Donate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9131-2592","authenticated-orcid":false,"given":"Agust\u00edn","family":"Albillos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.aohep.2026.102468_bib0001","first-page":"1453","article-title":"Coagulopathy of chronic liver disease","volume":"365","author":"Violi","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.aohep.2026.102468_bib0002","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/hep.21231","article-title":"Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity","volume":"44","author":"Lisman","year":"2006","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.aohep.2026.102468_bib0003","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/jth.15239","article-title":"The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease","volume":"19","author":"Lisman","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.aohep.2026.102468_bib0004","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1002\/hep.32019","article-title":"Risk and Outcome of Venous and Arterial Thrombosis in Patients With Cirrhosis: A Danish Nation-wide Cohort Study","volume":"74","author":"Jepsen","year":"2021","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.aohep.2026.102468_bib0005","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/ajg.2008.34","article-title":"Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study","volume":"104","author":"S\u00f8gaard","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.aohep.2026.102468_bib0006","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1160\/TH16-06-0450","article-title":"The risk of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis","volume":"117","author":"Ambrosino","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.aohep.2026.102468_bib0007","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.thromres.2022.05.004","article-title":"Incidence and prevalence of venous thromboembolism in chronic liver disease: A systematic review and meta-analysis","volume":"215","author":"Subhani","year":"2022","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.aohep.2026.102468_bib0008","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jhep.2023.02.023","article-title":"Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: The IMPORTAL competing-risk meta-analysis","volume":"79","author":"Guerrero","year":"2023","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2026.102468_bib0009","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2012.07.018","article-title":"Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis","volume":"143","author":"Villa","year":"2012","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.aohep.2026.102468_bib0010","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.jhep.2025.06.035","article-title":"Rivaroxaban to prevent complications of portal hypertension in cirrhosis: The CIRROXABAN study","volume":"83","author":"Puente","year":"2025","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.aohep.2026.102468_bib0011","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1016\/j.jtha.2024.05.023","article-title":"Anticoagulation for stroke prevention in atrial fibrillation and treatment of venous thromboembolism and portal vein thrombosis in cirrhosis: guidance from the SSC of the ISTH","volume":"22","author":"Carlin","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.aohep.2026.102468_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2026.109722","article-title":"DOACs in cirrhosis: Progress, pitfalls, and the path forward","volume":"262","author":"Loncharich","year":"2026","journal-title":"Thromb Res"},{"key":"10.1016\/j.aohep.2026.102468_bib0013","doi-asserted-by":"crossref","unstructured":"Tham D, Yu W, Zhao L, Kou R, Kherani J, Li PY, et al. Safety and efficacy of direct oral anticoagulants in patients with liver cirrhosis: a meta-analysis. Res Pract Thromb Haemost. 2025 Dec 12;10(1):103296. doi: 10.1016\/j.rpth.2025.103296. PMID: 41552757; PMCID: PMC12804106.","DOI":"10.1016\/j.rpth.2025.103296"},{"issue":"5","key":"10.1016\/j.aohep.2026.102468_bib0014","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2023.01.010","article-title":"Haemostasis in cirrhosis: Understanding destabilising factors during acute decompensation","volume":"78","author":"Zanetto","year":"2023","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.aohep.2026.102468_bib0015","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70378","article-title":"Haemostatic Balance and Transfusion Strategies in Acute Liver Failure and Acute-On-Chronic Liver Failure: A Systematic Review","volume":"45","author":"Ferdinande","year":"2025","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.aohep.2026.102468_bib0016","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1002\/hep.30103","article-title":"Coagulation Failure in Patients With Acute-on-Chronic Liver Failure and Decompensated Cirrhosis: Beyond the International Normalized Ratio","volume":"68","author":"Blasi","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.aohep.2026.102468_bib0017","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/hep.20569","article-title":"Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests","volume":"41","author":"Tripodi","year":"2005","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.aohep.2026.102468_bib0018","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70649","article-title":"Alterations in Primary Haemostasis in Patients With Liver Cirrhosis and Bacterial Infection","volume":"46","author":"Athanasaki","year":"2026","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.aohep.2026.102468_bib0019","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/jth.15562","article-title":"Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: Guidance from the SSC of the ISTH","volume":"20","author":"Roberts","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.aohep.2026.102468_bib0020","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/hep.21266","article-title":"Thrombin generation in patients with cirrhosis: the role of platelets","volume":"44","author":"Tripodi","year":"2006","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.aohep.2026.102468_bib0021","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jtha.2023.10.008","article-title":"Whole blood thrombin generation shows a significant hypocoagulable state in patients with decompensated cirrhosis","volume":"22","author":"Zanetto","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.aohep.2026.102468_bib0022","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jhep.2013.03.036","article-title":"Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis","volume":"59","author":"Tripodi","year":"2013","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2026.102468_bib0023","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jhep.2021.12.038","article-title":"Factor VIII\/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD","volume":"76","author":"Scheiner","year":"2022","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.aohep.2026.102468_bib0024","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.dld.2024.03.007","article-title":"Reticulated platelets are increased and hyper-activated in patients with cirrhosis, especially those with poor outcome","volume":"56","author":"Zanetto","year":"2024","journal-title":"Dig Liver Dis."},{"issue":"6","key":"10.1016\/j.aohep.2026.102468_bib0025","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/hep.510230613","article-title":"High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia","volume":"23","author":"Ferro","year":"1996","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.aohep.2026.102468_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2026.103370","article-title":"Total thrombus formation system exploration of primary hemostasis in cirrhotic patients","volume":"10","author":"Abdoul","year":"2026","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"10.1016\/j.aohep.2026.102468_bib0027","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/HEP.0000000000000349","article-title":"The evolving knowledge on primary hemostasis in patients with cirrhosis: A comprehensive review","volume":"79","author":"Zanetto","year":"2024","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.aohep.2026.102468_bib0028","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1053\/gast.2001.25481","article-title":"Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis","volume":"121","author":"Lisman","year":"2001","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.aohep.2026.102468_bib0029","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1053\/jhep.2003.50277","article-title":"Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis","volume":"38","author":"Colucci","year":"2003","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.aohep.2026.102468_bib0030","article-title":"Platelet protease nexin-1 limits fibrinolysis in patients with cirrhosis","volume":"7","author":"Riescher-Tuczkiewicz","year":"2025","journal-title":"JHEP Rep"},{"issue":"6","key":"10.1016\/j.aohep.2026.102468_bib0031","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/j.jtha.2025.02.034","article-title":"Patients with cirrhosis have a disbalance between coagulation and fibrinolysis resulting in a prothrombotic phenotype","volume":"23","author":"Willems","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.aohep.2026.102468_bib0032","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2024.2392028","article-title":"Fibrinogen dysfunction and fibrinolysis state in patients with hepatitis B-related cirrhosis","volume":"29","author":"Liu","year":"2024","journal-title":"Hematology"},{"issue":"3","key":"10.1016\/j.aohep.2026.102468_bib0033","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1053\/j.gastro.2023.05.046","article-title":"Procedural-Related Bleeding in Hospitalized Patients With Liver Disease (PROC-BLeeD): An International, Prospective, Multicenter Observational Study","volume":"165","author":"Intagliata","year":"2023","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.aohep.2026.102468_bib0034","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.jhep.2021.09.003","article-title":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis","volume":"76","year":"2022","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.aohep.2026.102468_bib0035","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jhep.2024.12.008","article-title":"Impaired whole blood thrombin generation is associated with procedure-related bleeding in acutely decompensated cirrhosis","volume":"82","author":"Zanetto","year":"2025","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2026.102468_bib0036","first-page":"1232","article-title":"Role of thrombosis in the pathogenesis of congestive hepatic fibrosis (cardiac cirrhosis)","volume":"21","author":"Wanless","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2026.102468_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.05.078","article-title":"Interruption of platelets and thrombin function as a new approach against liver fibrosis induced experimentally in rats","volume":"231","author":"Mahmoud","year":"2019","journal-title":"Life Sci"},{"issue":"5","key":"10.1016\/j.aohep.2026.102468_bib0038","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.22287","article-title":"Inhibition of activated factor X; a new pathway in ameliorating carbon tetrachloride-induced liver fibrosis in rats","volume":"33","author":"Mahmoud","year":"2019","journal-title":"J Biochem Mol Toxicol"},{"issue":"4","key":"10.1016\/j.aohep.2026.102468_bib0039","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jhep.2015.12.003","article-title":"Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats","volume":"64","author":"Cerini","year":"2016","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.aohep.2026.102468_bib0040","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/hep.29084","article-title":"The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells","volume":"65","author":"Vilaseca","year":"2017","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.aohep.2026.102468_bib0041","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/liv.13510","article-title":"Enoxaparin does not ameliorate liver fibrosis or portal hypertension in rats with advanced cirrhosis","volume":"38","author":"Fortea","year":"2018","journal-title":"Liver Int"},{"issue":"11","key":"10.1016\/j.aohep.2026.102468_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpet.2025.103749","article-title":"Mitigation of thromboinflammation by rivaroxaban ameliorates metabolic and structural manifestations of metabolic dysfunction-associated steatohepatitis in rats: Comparison to other antithrombotic drugs","volume":"392","author":"Rageh","year":"2025","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.aohep.2026.102468_bib0043","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/hep.31264","article-title":"Mortality and Hepatic Decompensation in Patients With Cirrhosis and Atrial Fibrillation Treated With Anticoagulation","volume":"73","author":"Serper","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2026.102468_bib0044","unstructured":"APEACH trial: Apixaban to Prevent Decompensation of Early Liver Cirrhosis Trial (APEACH). ClinicalTrials.gov ID NCT07726693"},{"issue":"1","key":"10.1016\/j.aohep.2026.102468_bib0045","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.dld.2025.09.018","article-title":"Recompensation after acute decompensation in alcohol-related cirrhosis is rare and likely unrelated to platelet-poor plasma thrombin generation and fibrinolysis","volume":"58","author":"Zanetto","year":"2026","journal-title":"Dig Liver Dis"},{"issue":"8","key":"10.1016\/j.aohep.2026.102468_bib0046","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000001003","article-title":"Increased thrombin generation is linked to first hepatic decompensation in patients with compensated cirrhosis","volume":"10","author":"Zanetto","year":"2026","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.aohep.2026.102468_bib0047","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejim.2022.05.032","article-title":"Epidemiology of portal vein thrombosis in liver cirrhosis: A systematic review and meta-analysis","volume":"104","author":"Pan","year":"2022","journal-title":"Eur J Intern Med"},{"issue":"2","key":"10.1016\/j.aohep.2026.102468_bib0048","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.27546","article-title":"Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study","volume":"61","author":"Nery","year":"2015","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.aohep.2026.102468_bib0049","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/gut.2004.042796","article-title":"Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation","volume":"54","author":"Francoz","year":"2005","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.aohep.2026.102468_bib0050","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.jhep.2021.07.020","article-title":"Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors","volume":"75","author":"Turon","year":"2021","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2026.102468_bib0051","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/liv.13500","article-title":"Decreased portal vein velocity is predictive of the development of portal vein thrombosis: A matched case-control study","volume":"38","author":"Stine","year":"2018","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.aohep.2026.102468_bib0052","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/HEP.0000000000001547","article-title":"Endothelial-to-mesenchymal transition: A targetable mechanism that contributes to portal vein thrombosis in cirrhosis","volume":"84","author":"Anton","year":"2026","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.aohep.2026.102468_bib0053","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S2468-1253(24)00155-9","article-title":"Portal vein thrombosis: diagnosis, management, and endpoints for future clinical studies","volume":"9","author":"Elkrief","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"26","key":"10.1016\/j.aohep.2026.102468_bib0054","first-page":"02778","article-title":"Baveno VIII - Advancing consensus in portal hypertension","volume":"S0168-8278","author":"Baveno","year":"2026","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.aohep.2026.102468_bib0055","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1111\/jgh.16263","article-title":"Natural history of portal vein thrombosis in cirrhosis: A systematic review with meta-analysis","volume":"38","author":"Giri","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2026.102468_bib0056","series-title":"Predictors and Prognostic Impact of Spontaneous Portal Vein Thrombosis Recanalization in Cirrhosis: an Individual Patient Data Meta-analysis","author":"Guerrero","year":"2026"},{"issue":"3","key":"10.1016\/j.aohep.2026.102468_bib0057","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/lt.24387","article-title":"Nontumoral portal vein thrombosis in patients awaiting liver transplantation","volume":"22","author":"Chen","year":"2016","journal-title":"Liver Transpl"},{"issue":"2","key":"10.1016\/j.aohep.2026.102468_bib0058","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14520","article-title":"Meta-analysis and systematic review: Prevalence, graft failure, mortality, and post-operative thrombosis in liver transplant recipients with pre-operative portal vein thrombosis","volume":"36","author":"Yeo","year":"2022","journal-title":"Clin Transplant"},{"issue":"11","key":"10.1016\/j.aohep.2026.102468_bib0059","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1111\/jth.15472","article-title":"Therapeutic anticoagulation after liver transplantation is not useful among patients with pre-transplant Yerdel-grade I\/II portal vein thrombosis: A two-center retrospective study","volume":"19","author":"Bos","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"8","key":"10.1016\/j.aohep.2026.102468_bib0060","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/lt.22105","article-title":"Portal vein thrombosis and liver transplant survival benefit","volume":"16","author":"Englesbe","year":"2010","journal-title":"Liver Transpl"},{"issue":"7","key":"10.1016\/j.aohep.2026.102468_bib0061","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.cgh.2012.01.012","article-title":"Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis","volume":"10","author":"Delgado","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.aohep.2026.102468_bib0062","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1007\/s10620-020-06695-4","article-title":"Safety, Efficacy, and Long-Term Outcomes of Anticoagulation in Cirrhotic Portal Vein Thrombosis","volume":"66","author":"Naymagon","year":"2021","journal-title":"Dig Dis Sci"},{"issue":"2","key":"10.1016\/j.aohep.2026.102468_bib0063","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41395-018-0421-0","article-title":"Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis","volume":"114","author":"Pettinari","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.aohep.2026.102468_bib0064","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.gastrohep.2018.06.005","article-title":"Efficacy and safety of anticoagulation in non-malignant portal vein thrombosis in patients with liver cirrhosis","volume":"41","author":"Artaza","year":"2018","journal-title":"Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.aohep.2026.102468_bib0065","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2017.04.042","article-title":"Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-analysis","volume":"153","author":"Loffredo","year":"2017","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.aohep.2026.102468_bib0066","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/HEP.0000000000000538","article-title":"Role of nonneoplastic PVT in the natural history of patients with cirrhosis and first diagnosis of HCC","volume":"79","author":"Senzolo","year":"2024","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.aohep.2026.102468_bib0067","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/liv.15435","article-title":"Increased platelet ratio in patients with decompensated cirrhosis indicates a higher risk of portal vein thrombosis","volume":"43","author":"Zanetto","year":"2023","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.aohep.2026.102468_bib0068","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1148\/radiol.2015150369","article-title":"Is Post-TIPS Anticoagulation Therapy Necessary in Patients with Cirrhosis and Portal Vein Thrombosis? A Randomized Controlled Trial","volume":"279","author":"Wang","year":"2016","journal-title":"Radiology"},{"issue":"7","key":"10.1016\/j.aohep.2026.102468_bib0069","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.14309\/ajg.0000000000001194","article-title":"Anticoagulation and Transjugular Intrahepatic Portosystemic Shunt for the Management of Portal Vein Thrombosis in Cirrhosis: A Prospective Observational Study","volume":"116","author":"Lv","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.aohep.2026.102468_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2025.102580","article-title":"Feasibility, Safety and Efficacy of Transjugular Intrahepatic Portosystemic Shunt for the Management of Portal Vein Thrombosis in Cirrhosis","volume":"15","author":"Conthe","year":"2025","journal-title":"J Clin Exp Hepatol"},{"issue":"7","key":"10.1016\/j.aohep.2026.102468_bib0071","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2015.27","article-title":"Cirrhosis is Associated with an Increased 30-Day Mortality After Venous Thromboembolism","volume":"6","author":"S\u00f8gaard","year":"2015","journal-title":"Clin Transl Gastroenterol"},{"issue":"3","key":"10.1016\/j.aohep.2026.102468_bib0072","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41424-018-0002-y","article-title":"Increased risk of venous thromboembolism in hospitalized patients with cirrhosis due to non-alcoholic steatohepatitis","volume":"9","author":"Stine","year":"2018","journal-title":"Clin Transl Gastroenterol"},{"issue":"10","key":"10.1016\/j.aohep.2026.102468_bib0073","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1111\/jth.15829","article-title":"Thromboprophylaxis for venous thromboembolism prevention in hospitalized patients with cirrhosis: Guidance from the SSC of the ISTH","volume":"20","author":"Roberts","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"7","key":"10.1016\/j.aohep.2026.102468_bib0074","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1111\/liv.15609","article-title":"Safety and efficacy of venous thromboembolism prophylaxis in patients with cirrhosis: A systematic review and meta-analysis","volume":"43","author":"Pasta","year":"2023","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.aohep.2026.102468_bib0075","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/MEG.0000000000002564","article-title":"Outcome of pharmacological thromboprophylaxis in hospitalized patients with cirrhosis - a systematic review and meta-analysis","volume":"35","author":"Giri","year":"2023","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2026.102468_bib0076","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/liv.12211","article-title":"Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhosis patients is not associated with high rates of gastrointestinal bleeding","volume":"34","author":"Intagliata","year":"2014","journal-title":"Liver Int"},{"issue":"13","key":"10.1016\/j.aohep.2026.102468_bib0077","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.jacc.2025.11.005","article-title":"2026 AHA\/ACC\/ACCP\/ACEP\/CHEST\/SCAI\/SHM\/SIR\/SVM\/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"87","author":"Creager","year":"2026","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.aohep.2026.102468_bib0078","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/MEG.0000000000001315","article-title":"Epidemiology of atrial fibrillation in patients with cirrhosis and clinical significance: a meta-analysis","volume":"31","author":"Chokesuwattanaskul","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.aohep.2026.102468_bib0079","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.jhep.2018.01.006","article-title":"Cirrhotic cardiomyopathy","volume":"69","author":"M\u00f8ller","year":"2018","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2026.102468_bib0080","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3390\/gastroent12010008","article-title":"Cirrhotic cardiomyopathy","volume":"12","author":"Longley","year":"2021","journal-title":"Gastroenterol Insights"},{"issue":"36","key":"10.1016\/j.aohep.2026.102468_bib0081","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.aohep.2026.102468_bib0082","first-page":"557","article-title":"Anticoagulation in patients with atrial fibrillation and liver cirrhosis","volume":"35","author":"Karapedi","year":"2022","journal-title":"Ann Gastroenterol"},{"issue":"2","key":"10.1016\/j.aohep.2026.102468_bib0083","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12668","article-title":"Atrial fibrillation, liver cirrhosis, thrombosis, and bleeding: A Danish population-based cohort study","volume":"6","author":"B Riahi","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"5","key":"10.1016\/j.aohep.2026.102468_bib0084","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011112","article-title":"Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation","volume":"8","author":"Lee","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.aohep.2026.102468_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2025.102534","article-title":"Efficacy and Safety of Direct Oral Anticoagulants Compared to Vitamin K Antagonists for Atrial Fibrillation in Patients With Liver Cirrhosis: An Update Systematic Review and Meta-analysis","volume":"15","author":"Miranda","year":"2025","journal-title":"J Clin Exp Hepatol"},{"issue":"14","key":"10.1016\/j.aohep.2026.102468_bib0086","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1001\/jama.2025.14679","article-title":"Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation: The ALONE-AF Randomized Clinical Trial","volume":"334","author":"Kim","year":"2025","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.aohep.2026.102468_bib0087","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/europace\/euad004","article-title":"Left atrial appendage closure device outcomes among cirrhosis patients with atrial fibrillation: a United States National Cohort Study","volume":"25","author":"Mir","year":"2023","journal-title":"Europace"},{"issue":"5","key":"10.1016\/j.aohep.2026.102468_bib0088","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/liv.13285","article-title":"Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis","volume":"37","author":"De Gottardi","year":"2017","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.aohep.2026.102468_bib0089","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2024.10.038","article-title":"AGA Clinical Practice Update on Management of Portal Vein Thrombosis in Patients With Cirrhosis: Expert Review","volume":"168","author":"Davis","year":"2025","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.aohep.2026.102468_bib0090","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/hep.31646","article-title":"Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases","volume":"73","author":"Northup","year":"2021","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.aohep.2026.102468_bib0091","doi-asserted-by":"crossref","first-page":"18","DOI":"10.14309\/ajg.0000000000000486","article-title":"ACG Clinical Guideline: Disorders of the Hepatic and Mesenteric Circulation","volume":"115","author":"Simonetto","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.aohep.2026.102468_bib0092","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/MCG.0b013e3181b3ab44","article-title":"Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis","volume":"44","author":"Amitrano","year":"2010","journal-title":"J Clin Gastroenterol"},{"issue":"10","key":"10.1016\/j.aohep.2026.102468_bib0093","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2021.05.013","article-title":"Comparison of Fondaparinux and Low-Molecular-Weight Heparin in the Treatment of Portal Vein Thrombosis in Cirrhosis","volume":"134","author":"Senzolo","year":"2021","journal-title":"Am J Med"},{"issue":"42","key":"10.1016\/j.aohep.2026.102468_bib0094","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008256","article-title":"Fondaparinux is effective for acute portal vein thrombosis in decompensated cirrhotic patients","volume":"96","author":"Zhang","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"10.1016\/j.aohep.2026.102468_bib0095","article-title":"Comparison of Apixaban, Rivaroxaban, Dabigatran, and Vitamin K Antagonists in Patients With Atrial Fibrillation and Liver Disease: A Network Meta-Analysis","volume":"16","author":"Shaikh","year":"2024","journal-title":"Cureus"},{"issue":"8","key":"10.1016\/j.aohep.2026.102468_bib0096","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1080\/00365521.2026.2672441","article-title":"Efficacy and safety of direct oral anticoagulants versus traditional anticoagulants in cirrhotic patients with venous thromboembolism and atrial fibrillation: a systematic review and meta-analysis","volume":"61","author":"Baysal","year":"2026","journal-title":"Scand J Gastroenterol"},{"issue":"11","key":"10.1016\/j.aohep.2026.102468_bib0097","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1055\/s-0043-1770100","article-title":"Risk of Bleeding in Liver Cirrhosis Receiving Direct Oral Anticoagulants: A Systematic Review and Meta-analysis","volume":"123","author":"Li","year":"2023","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.aohep.2026.102468_bib0098","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s11239-021-02424-4","article-title":"Safety of direct oral anticoagulants in patients with mild to moderate cirrhosis: a systematic review and meta-analysis","volume":"52","author":"Nisly","year":"2021","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"10.1016\/j.aohep.2026.102468_bib0099","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13397","article-title":"Direct oral anticoagulants and advanced liver disease: A systematic review and meta-analysis","volume":"51","author":"Menichelli","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.aohep.2026.102468_bib0100","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ijcard.2018.01.097","article-title":"Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants","volume":"264","author":"Pastori","year":"2018","journal-title":"Int J Cardiol"},{"issue":"8","key":"10.1016\/j.aohep.2026.102468_bib0101","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.7326\/M23-3067","article-title":"Comparative Effectiveness and Safety of Apixaban, Rivaroxaban, and Warfarin in Patients With Cirrhosis and Atrial Fibrillation: A Nationwide Cohort Study","volume":"177","author":"Simon","year":"2024","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.aohep.2026.102468_bib0102","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1161\/CIRCULATIONAHA.122.060687","article-title":"Comparative Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Chronic Liver Disease: A Nationwide Cohort Study","volume":"147","author":"Lawal","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.aohep.2026.102468_bib0103","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.thromres.2024.03.024","article-title":"Effectiveness and safety of direct oral anticoagulants among patients with non-valvular atrial fibrillation and liver disease: A multinational cohort study","volume":"237","author":"Douros","year":"2024","journal-title":"Thromb Res"},{"issue":"8","key":"10.1016\/j.aohep.2026.102468_bib0104","doi-asserted-by":"crossref","DOI":"10.1016\/j.gastha.2026.100996","article-title":"Direct Oral Anticoagulant Type and Dose in Atrial Fibrillation With Decompensated Cirrhosis: A Propensity-Matched Analysis","volume":"5","author":"Zanco","year":"2026","journal-title":"Gastro Hep Adv"},{"issue":"3","key":"10.1016\/j.aohep.2026.102468_bib0105","doi-asserted-by":"crossref","first-page":"265","DOI":"10.5114\/ceh.2023.130605","article-title":"Assessment of the efficiency and safety of anti-coagulation therapy in patients with liver cirrhosis and atrial fibrillation","volume":"9","author":"Baylo","year":"2023","journal-title":"Clin Exp Hepatol"},{"issue":"2","key":"10.1016\/j.aohep.2026.102468_bib0106","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jacc.2019.04.061","article-title":"Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease","volume":"74","author":"Qamar","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.aohep.2026.102468_bib0107","doi-asserted-by":"crossref","DOI":"10.1007\/s11239-026-03359-4","article-title":"Comparative outcomes of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and liver cirrhosis: A propensity score matched TriNetX analysis","author":"Ahmed","year":"2026","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"10.1016\/j.aohep.2026.102468_bib0108","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s12876-023-02960-8","article-title":"Comparison of the efficacy and safety between rivaroxaban and dabigatran in the treatment of acute portal vein thrombosis in cirrhosis","volume":"23","author":"Zhou","year":"2023","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"10.1016\/j.aohep.2026.102468_bib0109","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/apt.18474","article-title":"Experience With Dabigatran on Rate of Portal Vein Thrombosis Recanalization, Disease Progression and Survival","volume":"61","author":"Premkumar","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.aohep.2026.102468_bib0110","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/hepr.12895","article-title":"Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis","volume":"48","author":"Nagaoki","year":"2018","journal-title":"Hepatol Res"},{"issue":"1","key":"10.1016\/j.aohep.2026.102468_bib0111","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-60235-y","article-title":"Effectiveness of edoxaban in portal vein thrombosis associated with liver cirrhosis","volume":"14","author":"Tadokoro","year":"2024","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.aohep.2026.102468_bib0112","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/MEG.0000000000001958","article-title":"Evaluation of the efficacy and safety of direct oral anticoagulants in the treatment of portal vein thrombosis","volume":"33","author":"Ilcewicz","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.aohep.2026.102468_bib0113","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1182\/bloodadvances.2026019823","article-title":"Direct oral anticoagulants in portal vein thrombosis in patients with cirrhosis: a systematic review and meta-analysis","volume":"10","author":"Boccatonda","year":"2026","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.aohep.2026.102468_bib0114","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.dld.2021.07.039","article-title":"Efficacy and safety of direct oral anticoagulants versus vitamin K antagonist for portal vein thrombosis in cirrhosis: A systematic review and meta-analysis","volume":"54","author":"Koh","year":"2022","journal-title":"Dig Liver Dis"},{"issue":"4","key":"10.1016\/j.aohep.2026.102468_bib0115","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40268-021-00359-y","article-title":"Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment","volume":"21","author":"Frost","year":"2021","journal-title":"Drugs R D"},{"key":"10.1016\/j.aohep.2026.102468_bib0116","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2026.107030","article-title":"Pharmacokinetic robustness of direct oral anticoagulants vs. phenprocoumon in the emergency setting: impact of renal and hepatic impairment","author":"Merzou","year":"2026","journal-title":"Eur J Intern Med"},{"issue":"1","key":"10.1016\/j.aohep.2026.102468_bib0117","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bcp.12054","article-title":"Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor","volume":"76","author":"Kubitza","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.aohep.2026.102468_bib0118","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/jcph.550","article-title":"An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics","volume":"55","author":"Mendell","year":"2015","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.aohep.2026.102468_bib0119","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2025.08.001","article-title":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines on vascular diseases of the liver","volume":"84","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102468_bib0120","unstructured":"US Food and Drug Administration. Update on the safety of Andexxa: FDA safety communication. 2025."},{"key":"10.1016\/j.aohep.2026.102468_bib0121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000551185","article-title":"Main Lessons of the Recent Andexanet Withdrawal","author":"Sabouret","year":"2026","journal-title":"Cardiology"},{"issue":"9","key":"10.1016\/j.aohep.2026.102468_bib0122","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1111\/liv.14992","article-title":"Safety of direct oral anticoagulants in patients with advanced liver disease","volume":"41","author":"Semmler","year":"2021","journal-title":"Liver Int"},{"issue":"7","key":"10.1016\/j.aohep.2026.102468_bib0123","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.cgh.2020.08.007","article-title":"Rates of Bleeding and Discontinuation of Direct Oral Anticoagulants in Patients With Decompensated Cirrhosis","volume":"19","author":"Mort","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.aohep.2026.102468_bib0124","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jhep.2023.06.001","article-title":"A major research gap: The use of anticoagulants in cirrhosis","volume":"79","author":"Senzolo","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2026.102468_bib0125","unstructured":"COMBAT Trial: A Novel COMBinATorial Therapy With Albumin and Enoxaparin in Patients With Decompensated Cirrhosis at High-risk of Poor Outcome (CO). ClinicalTrials.gov ID NCT05895136."},{"key":"10.1016\/j.aohep.2026.102468_bib0126","doi-asserted-by":"crossref","DOI":"10.1177\/17562848261439217","article-title":"Continuous versus intermittent anticoagulation during endoscopic treatment of esophageal varices in cirrhosis: a randomized controlled trial","volume":"19","author":"He","year":"2026","journal-title":"Ther Adv Gastroenterol"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268126002887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268126002887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T07:03:01Z","timestamp":1792393381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268126002887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":126,"alternative-id":["S1665268126002887"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2026.102468","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticoagulation in cirrhosis: Indications, drug selection, and disease-modifying potential","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2026.102468","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"102468"}}